In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene ( PEARL ) trial , women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease ( CHD ) events and stroke , whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke .
